Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
24.45
-0.39 (-1.57%)
Streaming Delayed Price
Updated: 10:54 AM EDT, Jun 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Beam Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine
May 09, 2024
These biotech breakthrough stocks give investors a glimpse into medicine's future -- and massive moneymaking opportunities to boot.
Via
InvestorPlace
BEAM Stock Earnings: Beam Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 07, 2024
BEAM stock results show that Beam Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Expert Ratings For Beam Therapeutics
April 23, 2024
Via
Benzinga
Popular Crypto Trader Shares 2024 Predictions For These Three Altcoins
April 12, 2024
Popular pseudonymous crypto analyst Altcoin Sherpa on Friday shared his insights on three altcoins: Beam (CRYPTO: BEAM), Arbitrum (CRYPTO: ARB), and Render (CRYPTO:
Via
Benzinga
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol
April 02, 2024
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with...
Via
Benzinga
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts
March 27, 2024
Via
Benzinga
Navigating 4 Analyst Ratings For Beam Therapeutics
February 28, 2024
Via
Benzinga
Recap: Beam Therapeutics Q4 Earnings
February 27, 2024
Via
Benzinga
Is Beam Therapeutics Stock a Buy Now?
November 18, 2023
It has plenty of money, but it'll be facing plenty of competition, too.
Via
The Motley Fool
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat
February 27, 2024
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.
Via
Investor's Business Daily
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug
February 27, 2024
Both companies are working on treatments for genetic disorders.
Via
Investor's Business Daily
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Via
Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement
February 16, 2024
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday.
Via
Investor's Business Daily
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss
February 08, 2024
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: February 2024
February 07, 2024
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities
Via
InvestorPlace
Why Beam Therapeutics Stock Zoomed 17% Higher Today
January 29, 2024
JPMorgan Chase becomes the latest institution in the company's bull pen.
Via
The Motley Fool
Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K
January 16, 2024
Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by
Via
Benzinga
Topics
ETFs
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.
Via
InvestorPlace
Exposures
Product Safety
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
January 16, 2024
Analysts have high hopes for these three innovation companies in 2024.
Via
The Motley Fool
3 Stocks to Buy in the Booming Field of Gene Editing
January 11, 2024
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains.
Via
InvestorPlace
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
January 08, 2024
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run.
Via
The Motley Fool
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
2 Cathie Wood Stocks That Could Soar in 2024, According to Wall Street
December 27, 2023
Wall Street is uber-bullish on these two Ark Invest holdings.
Via
The Motley Fool
Lululemon To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Friday
December 08, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
December 04, 2023
The gene-editing revolution is unfolding at a record pace. Still, risks abound, and picking individual stocks may not be the wisest approach.
Via
The Motley Fool
Cathie Wood's ARK Innovation ETF Achieves 35% Gain In November, Its Best Month Since Inception
November 29, 2023
The ARK Innovation ETF (NYSE:ARKK), managed by renowned investor Cathie Wood, has posted remarkable gains in November, making it the fund’s best-performing month since its launch in 2014.
Via
Benzinga
Topics
ETFs
The 3 Best Gene Editing Stocks on the Frontier of Medicine
November 20, 2023
Some of the best gene editing stocks could soon see a massive boost from these two massive catalysts in December.
Via
InvestorPlace
3 Monster Stocks in the Making
November 18, 2023
These stocks could grow much larger over the next few years.
Via
The Motley Fool
Right Now Could Be a Once-in-a-Generation Opportunity to Buy These Cathie Wood Stocks
November 14, 2023
You might not get a better chance to invest in these disruptive companies.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.